Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Comparative-effectiveness how-to

This article was originally published in The Gray Sheet

Executive Summary

Agency for Healthcare Research and Quality is circulating a 1draft guide for conducting comparative-effectiveness reviews of medical technology and treatments. The guide addresses key methodological issues and the assessment of evidence quality. Comparative-effectiveness research has become a hot topic among policymakers who see potential cost-savings from better informed treatment guidelines, and a Medicare package bill expected to be introduced this year could provide funding for a new comparative-effectiveness center (2"The Gray Sheet" Oct. 1, 2007, p. 12). Comments on AHRQ's draft guide are due Nov. 7

You may also be interested in...



Comparative Effectiveness Will Likely Appear In Medicare Package This Year

Creating a national infrastructure for comparative effectiveness research has been flagged as a priority for inclusion in a Medicare package that Congress could consider before the end of the year

Chloroquine ‘Approval’ For COVID-19 And The US FDA’s New Reality

Asking whether FDA’s decision to allow emergency use of two old anti-malarial drugs was ‘political’ misses the point. The issue already was political, and FDA’s action may well be the best way to keep some measure of federal control on supplies of a drug with important other uses.

Biopharma, Payers Seek National Guidelines For Prescribing Potential COVID-19 Drugs

Guidelines for health care providers could help prevent shortages as demand for possible treatments surge, groups say. Stakeholders also argue “Buy America” executive order would hamper drug access.

Topics

UsernamePublicRestriction

Register

MT025360

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel